PrEP Implementation for Mothers in Antenatal Care
Launched by UNIVERSITY OF WASHINGTON · Feb 27, 2017
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
Women living in regions with high HIV prevalence are at high risk of HIV acquisition in pregnancy and postpartum because they infrequently use condoms, do not know their partner's HIV status, and have biologic changes or changes in their partner's sexual partnerships that increase susceptibility. Oral pre-exposure antiretroviral prophylaxis (PrEP) may be an attractive strategy for HIV prevention in pregnancy/postpartum; however, it is important to ensure PrEP reaches women who are at risk for acquiring HIV during pregnancy while avoiding unnecessary PrEP use during pregnancy. Clinicians and...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Eligibility for enrollment will include age ≥15 years
- • Pregnant at any gestational age
- • Tuberculosis negative
- • Plans to reside in area for at least one year postpartum
- • Plans to receive postnatal and infant care at the study facility
- • Not currently enrolled in any other studies.
- Exclusion Criteria:
- • HIV+ at time of enrollment
About University Of Washington
The University of Washington (UW) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust network of interdisciplinary teams, UW fosters collaboration among top-tier researchers, clinicians, and healthcare professionals, aiming to translate scientific discoveries into impactful treatments and interventions. The university is dedicated to ethical research practices and participant safety, ensuring rigorous adherence to regulatory standards in all clinical trials. Through its state-of-the-art facilities and extensive expertise, UW strives to address pressing health challenges and improve patient outcomes on a local and global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ambira, , Kenya
Bondo, , Kenya
Homa Bay, , Kenya
Kandiege, , Kenya
Kendu Bay, , Kenya
Madiany, , Kenya
Malanga, , Kenya
Marindi, , Kenya
Mbita, , Kenya
Ndhiwa, , Kenya
Ober, , Kenya
Ongielo, , Kenya
Rachuonyo South, , Kenya
Rangwe, , Kenya
Rwambwa, , Kenya
Siaya, , Kenya
Suba, , Kenya
Usigu, , Kenya
Uyawi, , Kenya
Yala, , Kenya
Patients applied
Trial Officials
Grace John-Stewart, MD, PhD
Principal Investigator
University of Washington
Jared Baeten, MD, PhD
Principal Investigator
University of Washington
John Kinuthia, MBChB, MMed
Study Director
Kenyatta National Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials